Intermittent Porphyria

• CLINICAL_TRIALS trial_result · 2026-01-30
  Clinical Trial Update: Panhematin for Prevention of Acute Attacks of Porphyria [Phase 2]

  Phase 2 study of Panhematin (hemin) to prevent acute attacks in porphyrias was terminated, with results posted on 2026-01-30.

• CLINICAL_TRIALS trial_result · 2024-03-12
  Clinical Trial Update: A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) [Phase 1, Phase 2]

  A study evaluating long-term safety and clinical activity of givosiran (ALN-AS1) in patients with acute intermittent porphyria has completed…

• CLINICAL_TRIALS trial_result · 2020-02-11
  Clinical Trial Update: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) [Phase 3]

  Phase 3 trial evaluating givosiran (ALN-AS1) for acute hepatic porphyrias has been completed with results posted.

• CLINICAL_TRIALS trial_result · 2019-01-25
  Clinical Trial Update: INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

  A terminated Alnylam-sponsored study (INSIGHT-AHP) sought to characterize the prevalence of acute hepatic porphyrias among patients with cli…

• CLINICAL_TRIALS trial_result · 2018-06-14
  Clinical Trial Update: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) [Phase 1]

  This clinical trial update reports the completion of a Phase 1 study of givosiran (ALN-AS1) in patients with Acute Intermittent Porphyria.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2018-03-09
  Clinical Trial Update: Porphozym in the Treatment of Acute Attacks in AIP [Phase 2, Phase 3]

  Porphozym is studied in a Phase 2/Phase 3 trial for acute attacks in Acute Intermittent Porphyria. The trial status is completed.

• CLINICAL_TRIALS trial_result · 2017-10-13
  Clinical Trial Update: Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride [Phase 1]

  Phase 1 study assessing intra-subject variability in the bioavailability of chlorpromazine hydrochloride. The study is completed and results…

• CLINICAL_TRIALS trial_result · 2014-12-18
  Clinical Trial Update: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria [Phase 1]

  A Phase I gene therapy trial using the rAAV2/5-PBGD vector for acute intermittent porphyria has completed.